Clinical Trial Update: An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing anidulafungin to caspofungin for serious Candida infections in immunocompromised patients was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Invasive Candidiasis

Drugs mentioned

• Cancidas (caspofungin)
• Eraxis (anidulafungin)

Snippet

Sponsor: Pfizer | Conditions: Fungemia, Neutropenia | Phase 3 | Status: TERMINATED | Results posted: 2012-12-20